

# Colon Case Study

onco*type* DX<sup>®</sup>  
Colon Cancer Assay

## 67-Year-Old Female Patient

**Tumor Type** Adenocarcinoma

**Tumor Stage** Stage III A/B (N1-3)

**Histologic Grade** Low (1)

**Lymph Node Status** Positive

**Number of Lymph Nodes Assessed** 15

**Mismatch Repair (MMR) Status** MMR-P (MSS)

**Lymphovascular Invasion** Absent

**Perforation** Absent

**Obstruction** Absent

**Other Information** Patient has hypertension, P.E

Treatment: Capecitabine (Xeloda) and Oxaliplatin

### CASE SUBMITTED BY:

Putacena MD

University of Texas

Houston TX

# Colon Case Study


## CLINICAL EXPERIENCE

Recurrence Score = 13

### Prognosis for Stage III A/B Colon Cancer Patients Following Adjuvant Chemotherapy

The clinical validation study included patients from the NSAPB C-07 trial which randomized 409 stage III A/B patients to 5FU/LV versus 5FU/LV+oxaliplatin.<sup>1</sup>

The average 5 year risk of recurrence for patients who had a Recurrence Score<sup>®</sup> result of 13 was:



Other Considerations: The recurrence risk for patients with ≥ 12 nodes examined was lower than the risk for those with < 12 nodes examined.

#### References:

1. Yothers et al. J Clin Oncol. 2013.